CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

9774	Companies
195575	Keywords
126557	Articles
103967	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 2 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 2 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 3 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 3 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 4 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 4 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 4 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 4 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 4 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 4 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 01/30/2026 at 02:15, 3 hours 48 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 6 hours 3 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 7 hours 3 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 11 hours 18 minutes ago

Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 12 hours 3 minutes ago

PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 04:30, 1 hour 33 minutes ago

A First Look at AI in the Real World: AWE 2026 Opens This March in Shanghai
Published on 01/30/2026 at 03:35, 2 hours 28 minutes ago

Bybit Unveils 2026 Vision as "The New Financial Platform," Expanding Beyond Exchange Into Global Financial Infrastructure
Published on 01/30/2026 at 00:07, 5 hours 55 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 9 hours ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 21:01, 9 hours 2 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc

Les Echos

Published on 01/29/2026 at 18:00, 12 hours 3 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 12 hours 18 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 12 hours 18 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 12 hours 23 minutes ago

ALTEN: Annual revenue 2025
Published on 01/29/2026 at 10:07, 19 hours 56 minutes ago

Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech

View all LES ECHOS COMFI WIRE